Skip to main content

Table 3 Frequent (≥20%) reported adverse events across dose levels 3–4 that were considered related to both foretinib and lapatinib

From: A phase-I study of lapatinib in combination with foretinib, a c-MET, AXL and vascular endothelial growth factor receptor inhibitor, in human epidermal growth factor receptor 2 (HER-2)-positive metastatic breast cancer

 

Adverse events

Grade 1–2

Grade 3

Grade 4

Dose level 3 (n = 6)

   

Diarrhea

6

 

Nausea

6

 

Vomiting

4

1

Fatigue

5

 

Anorexia

5

 

Proteinuria

4

 

Thromboembolic

1

2

Anemia

4

 

AST and/or ALT elevation

5/6

 

Dose level 4 (n = 7)

   

Diarrhea

2

5

Nausea

7

 

Vomiting

5

 

Fatigue

5

2

Anorexia

5

 

Proteinuria

2

1

Edema (limbs)

2

 

Myalgia

3

 

Hypertension

4

 

Anemia

2

 

AST and/or ALT elevation

5/4

2/3

  1. AST aspartate aminotransferase, ALT alanine aminotransferase
Back to article page

Breast Cancer Research

ISSN: 1465-542X

Contact us